Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Department of Pharmacology and Physiology and the Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO, 63104, USA.
Purinergic Signal. 2023 Sep;19(3):465-466. doi: 10.1007/s11302-023-09964-9.
Receptor agonists and antagonists and other modulators of purinergic signalling have potential as novel therapeutics for a broad range of diseases and conditions. This special issue focuses on compounds or approaches that are either in clinical trials or headed in that direction. It is intended to serve as an up-to-date description of selected efforts to discover and develop new small molecular purinergic drugs.
激动剂和拮抗剂以及其他嘌呤能信号转导的调节剂有可能成为广泛疾病和病症的新型治疗药物。本期特刊重点介绍了处于临床试验或朝这一方向发展的化合物或方法。它旨在作为发现和开发新型小分子嘌呤能药物的精选努力的最新描述。
